Viatris (VTRS) has agreed to acquire Pacira BioSciences (PCRX) for $1.65 billion in cash at $36.50 per share, expected to close by end of 2026. The acquisition adds two marketed pain therapies (Exparel and Zilretta) generating $350.5 million in H1 2026 sales, plus a mid-stage gene therapy candidate (PCRX-201) for knee osteoarthritis. The deal is expected to be immediately accretive to Viatris' financial metrics and strengthen its non-opioid pain management portfolio.

Pacira BioSciences surged 44% after announcing its acquisition by Viatris for $36.50 per share, valuing the company at approximately $1.65 billion. The deal represents a 45% premium to the previous closing price and is expected to close by end of 2026. Viatris plans to leverage Pacira's non-opioid pain management products, including Exparel and Zilretta, to strengthen its innovative medicines business.

Pacira BioSciences announced an exclusive agreement with Italian pharmaceutical company Molteni Farmaceutici to distribute and commercialize Exparel across the EU and UK. Molteni will launch the long-acting local anesthetic in Italy, Germany, Austria, and Poland starting in 2027, while Pacira retains manufacturing rights and will receive upfront payments, supply fees, and royalties. The deal supports Pacira's international expansion strategy while the company advances other pain management products including Zilretta and PCRX-201.

Pacira (PCRX) reported Q2 2026 adjusted earnings of 73 cents per share, beating consensus estimates of 64 cents, with revenues of $192.4 million exceeding expectations. However, the company lowered its 2026 total revenue guidance to $735-$760 million from $745-$770 million following the divestiture of iovera to Zimmer Biomet. Despite the earnings beat, estimates have been trending downward, and the stock received a Zacks Rank #3 (Hold) rating with expectations for in-line returns.

Pacira BioSciences announced it will report its second quarter 2026 financial results on August 4, 2026, followed by a live conference call and webcast at 4:30 p.m. ET. The company is a leader in non-opioid pain therapies with three commercial-stage treatments: EXPAREL, ZILRETTA, and iovera, plus a pipeline of clinical-stage assets including PCRX-201 in Phase 2 development for osteoarthritis.

Pacira BioSciences granted inducement equity awards to ten new employees on July 2, 2026, consisting of stock options for 9,200 shares and restricted stock units for 18,200 shares. The awards were approved by the People & Compensation Committee under Nasdaq Listing Rule 5635(c)(4) without stockholder approval.

The osteoarthritis market is projected to grow at a 3% CAGR from 2026 to 2036, reaching USD 32.5 billion in 2025 across seven major markets. Growth is driven by an aging population, rising disease prevalence, and the launch of emerging therapies including LEVI-04, ZILOSUL, TissueGene-C, and AMZ001. Current treatment is dominated by opioids, but novel disease-modifying therapies and regenerative medicine approaches are expected to reshape the market landscape.

Pacira BioSciences announced inducement equity awards to ten new employees on May 4, 2026, including stock options for 36,800 shares and restricted stock units for 27,700 shares. The awards were granted under the company's Amended and Restated 2014 Inducement Plan with an exercise price of $24.69 per share.

Pacira BioSciences CFO Shawn Cross exercised and sold 12,941 shares for approximately $326,000 on April 23, 2026, representing 10.94% of his direct holdings. The transaction was part of a pre-planned Rule 10b5-1 trading plan. Despite the insider sale, the company reported strong Q1 2026 results with $177 million in revenue (5% YoY growth) and beat analyst expectations, with the stock rising about 12% in April.

Pacira BioSciences presented real-world data demonstrating that EXPAREL (bupivacaine liposome injectable suspension) is associated with lower total healthcare costs and reduced opioid utilization in outpatient total hip and knee arthroplasty procedures. Three studies showed cost savings ranging from $7,332 to $13,022 over 6 months post-surgery, with a projected cumulative cost difference of $117,868 per 1 million members by year 3 compared to ropivacaine.

Pacira BioSciences announced inducement equity awards to three new employees on March 3, 2026, including stock options for 2,400 shares and restricted stock units for 5,500 shares. The awards were granted under the company's Amended and Restated 2014 Inducement Plan with an exercise price of $22.10 per share.

The global corticosteroids market is projected to grow from USD 6.24 billion in 2025 to USD 8.45 billion by 2031 at a CAGR of 5.18%, driven by rising chronic diseases like asthma and COPD. However, safety concerns from prolonged usage and a shift toward biologics and localized therapies present significant challenges. Innovations in drug delivery systems and extended-release formulations are reshaping the market.